Effects of Silybum Marianum on Treatment of Patients With Chronic Hepatitis C

Isfahan University of Medical Sciences55 enrolled

Overview

The purpose of this study is to determine the effects of silymarin on outcomes of patients with hepatitis C.

Silymarin has been claimed to have a beneficial effect in various types of liver injury, including alcoholic liver disease, drug and toxin induced hepatotoxicity, and acute and chronic viral hepatitis.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

SINGLE

Enrollment

Conditions

Hepatitis C

Interventions

SilymarinDRUG

Tab 210 mg, 630 mg, daily, six months.

Eligibility

Sex: ALLHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: confirmed chronic hepatitis C (HCV Ab (+), HCV RNA (with PCR) (+)) normal or increased liver enzymes (ALT and AST) not using interferon or ribavirin due to patient sensitivity or not consenting. Exclusion Criteria: The pregnant patients patients with side effect which confirmed with rechallenge test

Locations (1)

Al-zahra university hospital

Isfahan, Isfahan, Iran

Outcomes

Primary Outcomes

Serum aminotransferases (ALT, AST)

The investigators measured serum amino transferases by commercial AST kit,. ALT kits(Bayer Diagnostics,. Tarrytown, NY, USA) at six months after silymarin admission

Time frame: at six months after admission

Secondary Outcomes

HCV-RNA

The investigators measured serum HCV-RNA by Polymerase Chain Reaction (PCR) at six months after silymarin admission

Time frame: at six months after admission

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.